Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.

@article{Reddy2008PradefovirAP,
  title={Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.},
  author={Kondreddy Raja Reddy and Michael C. Matelich and Bheemarao G. Ugarkar and Jorge E. Gomez-Galeno and Jay Dare and Kristin P. Ollis and Zhili Sun and William A Craigo and Timothy J. Colby and James M. Fujitaki and Serge H. Boyer and Paul D. van Poelje and Mark D. Erion},
  journal={Journal of medicinal chemistry},
  year={2008},
  volume={51 3},
  pages={
          666-76
        }
}
Adefovir dipivoxil, a marketed drug for the treatment of hepatitis B, is dosed at submaximally efficacious doses because of renal toxicity. In an effort to improve the therapeutic index of adefovir, 1-aryl-1,3-propanyl prodrugs were synthesized with the rationale that this selectively liver-activated prodrug class would enhance liver levels of the active metabolite adefovir diphosphate (ADV-DP) and/or decrease kidney exposure. The lead prodrug (14, MB06866, pradefovir), identified from a… 
Factors limiting the extent of absolute bioavailability of pradefovir in rat
TLDR
Rat intestines’ Ussing chamber experiment indicated that P-glycoprotein (P-gp) transporter and paracellular pathway may involve in intestinal transportation, suggestive for the disposition of pradefovir in human intestine and liver.
Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects
TLDR
The single oral dose of pradefovir 10–120 mg was well tolerated and three metabolism-related single nucleotide polymorphism (SNP) locis, P450 (cytochrome) oxidoreductase [POR] and CYP2F1 (rs305968)], and one distribution-related loci, orosomucoid 2 [ORM2 (rs12685968)].
Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro.
TLDR
The in vitro potential of a particular statin, simvastatin (SIM), exhibits strong in vitro anti-HBV activity, and may greatly augment anti- HBV therapy clinically.
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
TLDR
A series of novel O-(substituted benzyl) phosphoramidate prodrugs of 5-fluoro-2'-deoxyuridine for the treatment of hepatocellular carcinoma are reported, with the o-methylbenzyl analog (1t) identified as an orally bioavailable and liver-targeted lead compound.
Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors
TLDR
Covering diverse chemical structures and mechanisms of action, non‐nucleos(t)ide compounds offer great promise in the search for new anti‐HBV drugs.
Cytochrome P450-activated prodrugs.
TLDR
The activation of prodrugs by the cytochrome P450 system provides a highly versatile approach to prodrug design that is particularly adaptable for targeting drug activation to the liver, to tumors or to hypoxic tissues.
Cytochrome P450-activated prodrugs.
A prodrug is a compound that has negligible, or lower, activity against a specified pharmacological target than one of its major metabolites. Prodrugs can be used to improve drug delivery or
Simultaneous determination of pradefovir, PMEA and tenofovir in HBV patient serum using liquid chromatography-tandem mass spectrometry and application to phase 2 clinical trial.
TLDR
A rapid and sensitive liquid chromatography-tandem mass spectrometry method was developed and validated and successfully applied to the pharmacokinetic study of pradefovir, adefovir dipivoxil and tenofovir disoproxil fumarate in a set of HBV patients.
2′‐Fluoro‐6′‐methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti‐HBV agent, active against drug‐resistant HBV mutants
TLDR
Preclinical studies of FMCA and its phosphoramidate prodrug (FMCAP) have been summarized and potential anti‐HBV activity against adefovir, as well as lamivudine (LMV/LAM) drug‐resistant mutants is demonstrated.
Phosphoramidates and phosphonamidates (ProTides) with antiviral activity
TLDR
In this review, the seminal contribution of Chris McGuigan’s research to this field is presented and his technology proved to be extremely successful in drug discovery and has led to two Food and Drug Administration-approved antiviral agents.
...
1
2
3
4
5
...